In this article, published in June's edition of Pharmafocus, our Advisory Board Members, Mel Walker and Yngve Mikkelsen provide an insight into how global events can impact patient access in a real-world setting.

Decisions on reimbursement of medicines must strike a balance between health benefits and healthcare budgets. Healthcare decision-makers rely heavily on health technology assessment (HTA) agencies to achieve greater value for money.  A high level of uncertainty reduces the willingness to pay for new technologies.

This article goes through several environmental factors which all emphasise the need to start thinking about HTA and commercial requirements early in the development process and build a strategy that meets the needs of regulators as well as payers.

New drugs are launched in an uncertain, perhaps yet unknown, future market and unpredictable events such as the covid-19 pandemic, new technologies, lack of data, US drug pricing and the new regulatory landscape in the UK can also impact market access.

Under these circumstances, evidence generation must be matched with the needs of all future stakeholders.

Read More

To learn more about how you as a developer can future proof your portfolio, contact our experts at

The Authors

Dr Mel Walker

Advisory Board Member

Read more

Dr Yngve Mikkelsen

Advisory Board Member

Read More

Stay up to date

Contact us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World

  • This field is for validation purposes and should be left unchanged.